MARKET

GOVXW

GOVXW

GEOVAX LABS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9850
-0.0554
-5.62%
After Hours: 0.9228 -0.0622 -6.31% 18:29 01/21 EST
OPEN
0.8001
PREV CLOSE
0.9850
HIGH
1.000
LOW
0.8000
VOLUME
80
TURNOVER
--
52 WEEK HIGH
4.480
52 WEEK LOW
0.8000
MARKET CAP
--
P/E (TTM)
-0.8510
1D
5D
1M
3M
1Y
5Y
BRIEF-Geovax Announces Closing Of $10 Million Private Placement
reuters.com · 1d ago
GeoVax Announces Closing of $10 Million Private Placement
Atlanta, GA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today the closing of its previously announced priva...
GlobeNewswire · 1d ago
GeoVax Announces $10 Million Private Placement
Atlanta, GA, Jan. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it has entered into a securities purchas...
GlobeNewswire · 01/14 13:41
GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial
Activities Underway to Expand and Accelerate Enrollment of Ongoing Study for Head and Neck Cancer ATLANTA, GA, Jan. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human ...
GlobeNewswire · 01/13 14:00
BRIEF-GeoVax Appoints Kelly Mckee As Chief Medical Officer
reuters.com · 01/11 14:08
GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer
Atlanta, GA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the appointment of Kelly T. McKee, Jr., M.D.,...
GlobeNewswire · 01/11 14:00
GeoVax to Participate in Upcoming Life Sciences Investor Conferences
Conference Presentation to Include Updates on Three Ongoing Phase 2 Clinical Trials for COVID-19 and Cancer Atlanta, GA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherap...
GlobeNewswire · 01/05 14:00
GeoVax Issues Shareholder Update Letter
Letter from CEO Describes Achievements during 2021 and Sets Forth New Goals for 2022 ATLANTA, GA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and ...
GlobeNewswire · 01/04 14:00
More
Forecast
Actual (M USD)
Estimate (M USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GOVXW. Analyze the recent business situations of GEOVAX LABS through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
Actual
Estimate
-1840.00-1380.00-920.00-460.00
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.82%
Pharmaceuticals & Medical Research
-1.11%
Key Executives
Chairman/President/Chief Executive Officer/Director
David Dodd
Chief Financial Officer/Secretary
Mark Reynolds
Chief Scientific Officer
Mark Newman
Chief Scientific Officer
Harriet Robinson
Director
Robert McNally
Independent Director
Randal Chase
Independent Director
Dean Kollintzas
Independent Director
John Spencer
No Data
About GOVXW
GeoVax Labs, Inc. (GeoVax) is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapies and vaccines against cancers and infectious diseases using a vector vaccine platform (Modified Vaccinia Ankara-Virus Like Particle or GV-MVA-VLP). It is focused on developing a vaccine for prevention of coronavirus (COVID-19) infection. The GV-MVA-VLP platform provides design and test vaccine to candidates, which differ through the inclusion of multiple SARS-CoV-2 proteins that are presented to the immune system as virus-like particles (VLPs). The Company's development programs are focused on preventive vaccines against hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa fever), Zika virus and malaria; preventive and therapeutic vaccines against Human Immunodeficiency Virus (HIV); as well as immunotherapies for solid tumor cancers. The Company is developing vaccines and immunotherapies for prevention or treatment of infectious diseases and cancer.

Webull offers kinds of Geovax Labs Inc stock information, including NASDAQ:GOVXW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GOVXW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GOVXW stock methods without spending real money on the virtual paper trading platform.